Polymorphisms of the SLCO1B1 gene predict methotrexate‐related toxicity in childhood acute lymphoblastic leukemia
Pediatric Blood & Cancer2011Vol. 57(4), pp. 612–619
Citations Over TimeTop 1% of 2011 papers
Elixabet López-López, Idoia Martín‐Guerrero, Javier Ballesteros, M.A. Piñán, Purificación García‐Miguel, Aurora Navajas, África García‐Orad
Abstract
Identification of the rs4149081 and rs11045879 SLCO1B1 polymorphisms in children with ALL could be a useful tool for monitoring patients at risk of low-MTX clearance in order to avoid MTX-related toxicity.
Related Papers
- → Influence of pharmacogenetics on the diversity of response to statins associated with adverse drug reactions(2023)7 cited
- Role of Pharmacogenetics on Response to Statins: A Genotype-based Approach to Statin Therapy Outcome(2014)
- → Prescriber Adoption of SLCO1B1Genotype‐Guided Simvastatin Clinical Decision Support in a Clinical Pharmacogenetics Program(2022)6 cited
- → Pharmacogenetics(2018)3 cited
- → Delayed Methotrexate Elimination after Administration of a Medium Dose of Methotrexate in a Patient with Genetic Variants Associated with Methotrexate Clearance.(2020)2 cited